FTXH stock icon

First Trust Nasdaq Pharmaceuticals ETF
FTXH

27.13 USD
+0.04
0.15%
At close Nov 19, 4:00 PM EST
1 day
0.15%
5 days
-5.11%
1 month
-4.71%
3 months
-6.90%
6 months
-0.04%
Year to date
-0.40%
1 year
10.33%
5 years
23.37%
10 years
32.73%
0
Funds holding %
of 6,735 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

3.71% more ownership

Funds ownership: 39.73% [Q2] → 43.45% (+3.71%) [Q3]

7% less capital invested

Capital invested by funds: $8.12M [Q2] → $7.54M (-$582K) [Q3]

13% less funds holding

Funds holding: 24 [Q2] → 21 (-3) [Q3]

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for FTXH.

See Analyst Rankings

Financial journalist opinion

Positive
Zacks Investment Research
3 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Solid Q2 Earnings
Positive
Zacks Investment Research
6 months ago
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
A Look at Pharma ETFs Post Q1 Earnings
Positive
Zacks Investment Research
7 months ago
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Neutral
Zacks Investment Research
9 months ago
A Look at Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
A Look at Pharma ETFs After Q4 Earnings
See News Rankings
Charts implemented using Lightweight Charts™